Covid-19 roundup: BAR­DA pumps $60M more in­to SAB treat­ment; EMA to de­cide on boost­ers next month

SAB Bio­ther­a­peu­tics said Thurs­day the US fed­er­al gov­ern­ment is pro­vid­ing it with an ad­di­tion­al $60.5 mil­lion, and more than $200 mil­lion in to­tal, to ad­vance its in­tra­venous poly­clon­al an­ti­body can­di­date for the treat­ment of Covid-19.

The treat­ment, known as SAB-185, is cur­rent­ly in a Phase II/III tri­al in non-hos­pi­tal­ized pa­tients with mild-mod­er­ate Covid-19 in­fec­tions at risk for dis­ease pro­gres­sion. It looks to be the third an­ti­body treat­ment for Covid-19 au­tho­rized in the US, fol­low­ing those from Re­gen­eron, Eli Lil­ly and GSK/Vir Biotech­nol­o­gy (which the fed­er­al gov­ern­ment is not dis­trib­ut­ing).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER